

Announcement Summary

Entity name EMVISION MEDICAL DEVICES LTD

Announcement Type

New announcement

Date of this announcement

Friday July 24, 2020

The Proposed issue is: ☑ A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
EMV	ORDINARY FULLY PAID	6,338,028

Proposed +issue date

Thursday July 30, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

EMVISION MEDICAL DEVICES LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

1.2 Registered Number Type

ABN

Registration Number

38620388230

1.3 ASX issuer code

EMV

1.4 The announcement is

Solution New announcement

1.5 Date of this announcement

Friday July 24, 2020

1.6 The Proposed issue is:

☑ A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

🕑 No

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? Securities class Will the proposed issue of this +security include an offer of attaching +securities? ℭNo

Details of +securities proposed to be issued

ASX +security code and description

EMV : ORDINARY FULLY PAID

Number of +securities proposed to be issued

6,338,028

Offer price details

In what currency is the cash consideration being paid?

What is the issue price per +security? AUD 1.42000

AUD - Australian Dollar

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? ☑ Yes



Part 7C - Timetable

7C.1 Proposed +issue date

Thursday July 30, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? ⓒ No

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

2,472,980

7D.1c (i) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?

3,865,048

7D.1c (ii) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate

Certainty of raising of the funds required and completion in a timely manner.

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? $\textcircled{\mbox{S}}$ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? So

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No

Part 7E - Fees and expenses



7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Management Fee - 3% of funds raised Selling Fee - 3% of funds raised

7E.2 Is the proposed issue to be underwritten?

🕑 No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

No other material fees or costs

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Ongoing product development, including the Company's first generation portable brain scanner for commercialisation, corporate administration and general working capital.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? ☑ No

7F.2 Any other information the entity wishes to provide about the proposed issue